Breaking News

SGS Adds Analyzer System for Biomarker Analysis

June 27, 2014

Expands support services for biologics development

SGS Life Science Services has acquired the Cobas 6000 Analyzer System Chemistry Module at its Poitiers lab to support the development of biologics. According to the company, the platform allows the determination of a large number of biomarkers and metabolites quickly (as little as two minutes) and reliability, using very small sample volumes. 
Using an "open" technology concept, the Cobas 6000 provides for easy-to-use reagents as well as those not provided by the manufacturer, promoting optimization of protocols and allowing SGS to offer additional tests that can be validated as well as to meet GLP requirements, according to the company. All results are entered directly into the Watson LIMS (Laboratory Information Management System) for traceability of analysis and can be grouped by patient even if the results are obtained during long-term kinetics.
"This progress will permit the SGS Poitiers site to provide more analysis of biomarkers in a GLP environment and complies with the latest guidelines of Good Clinical Practice (GCP)," said Alain Renoux, director of SGS Life Science Services, Poitiers. "From a clinical protocol compliance perspective, the Cobas System 6000 ensures traceability of the sample before and after dosing, and allows trial sponsors to limit the volume of biological matrix collected in the patient."
The company also recently completed the qualification of a new Hitachi L-8900 Amino Acid Analyzer at its lab in Clichy, near Paris. This instrument is used to perform the analysis of amino acids in compliance with pharmacopoeial requirements (EP Section 2.2.56 and USP <1052>).

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.